Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Sep;80(3):280-292.
doi: 10.1016/j.eururo.2020.11.010. Epub 2020 Dec 11.

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

Affiliations
Meta-Analysis

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

Luca F Valle et al. Eur Urol. 2021 Sep.

Abstract

Context: Management of locally recurrent prostate cancer after definitive radiotherapy remains controversial due to the perceived high rates of severe genitourinary (GU) and gastrointestinal (GI) toxicity associated with any local salvage modality.

Objective: To quantitatively compare the efficacy and toxicity of salvage radical prostatectomy (RP), high-intensity focused ultrasound (HIFU), cryotherapy, stereotactic body radiotherapy (SBRT), low-dose-rate (LDR) brachytherapy, and high-dose-rate (HDR) brachytherapy.

Evidence acquisition: We performed a systematic review of PubMed, EMBASE, and MEDLINE. Two- and 5-yr recurrence-free survival (RFS) rates and crude incidences of severe GU and GI toxicity were extracted as endpoints of interest. Random-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Estimates for each modality were then compared with RP after adjusting for individual study-level covariates using mixed-effect regression models, while allowing for differences in between-study variance across treatment modalities.

Evidence synthesis: A total of 150 studies were included for analysis. There was significant heterogeneity between studies within each modality, and covariates differed between modalities, necessitating adjustment. Adjusted 5-yr RFS ranged from 50% after cryotherapy to 60% after HDR brachytherapy and SBRT, with no significant differences between any modality and RP. Severe GU toxicity was significantly lower with all three forms of radiotherapeutic salvage than with RP (adjusted rates of 20% after RP vs 5.6%, 9.6%, and 9.1% after SBRT, HDR brachytherapy, and LDR brachytherapy, respectively; p ≤ 0.001 for all). Severe GI toxicity was significantly lower with HDR salvage than with RP (adjusted rates 1.8% vs 0.0%, p < 0.01), with no other differences identified.

Conclusions: Large differences in 5-yr outcomes were not uncovered when comparing all salvage treatment modalities against RP. Reirradiation with SBRT, HDR brachytherapy, or LDR brachytherapy appears to result in less severe GU toxicity than RP, and reirradiation with HDR brachytherapy yields less severe GI toxicity than RP. Prospective studies of local salvage for radiorecurrent disease are warranted.

Patient summary: In a large study-level meta-analysis, we looked at treatment outcomes and toxicity for men treated with a number of salvage treatments for radiorecurrent prostate cancer. We conclude that relapse-free survival at 5 years is equivalent among salvage modalities, but reirradiation may lead to lower toxicity.

Keywords: Cryotherapy; High-dose-rate brachytherapy; High-intensity focused ultrasound; Low–dose-rate brachytherapy; Meta-analysis; Prostate cancer; Radiation therapy; Radical prostatectomy; Radiorecurrent prostate cancer; Salvage therapy; Stereotactic body radiotherapy.

PubMed Disclaimer

Figures

Fig. 1 –
Fig. 1 –
(A–F) Forest plots showing individual study values of 2-yr RFS estimates for various treatment modalities. CI = confidence interval; Cryo = cryotherapy; HDRBT = high-dose-rate brachytherapy; HIFU = high-intensity focused ultrasound; LDRBT = low-dose-rate brachytherapy; RFS = recurrence-free survival; RP = radical prostatectomy; SBRT = stereotactic body radiotherapy.
Fig. 2 –
Fig. 2 –
(A–E) Forest plots showing individual study values of 5-yr RFS estimates for various treatment modalities. CI = confidence interval; Cryo = cryotherapy; HDRBT = high-dose-rate brachytherapy; HIFU = high-intensity focused ultrasound; LDRBT = low-dose-rate brachytherapy; RFS = recurrence-free survival; RP = radical prostatectomy.
Fig. 3 –
Fig. 3 –
(A–F) Forest plots showing individual study values of severe GU toxicity estimates for various treatment modalities. CI = confidence interval; Cryo = cryotherapy; GU = genitourinary; HDRBT = high-dose-rate brachytherapy; HIFU = high-intensity focused ultrasound; LDRBT = low-dose-rate brachytherapy; RP = radical prostatectomy; SBRT = stereotactic body radiotherapy.
Fig. 4 –
Fig. 4 –
(A–F) Forest plots showing individual study values of severe GI toxicity estimates for various treatment modalities. CI = confidence interval; Cryo = cryotherapy; GI = gastrointestinal; HDRBT = high-dose-rate brachytherapy; HIFU = high-intensity focused ultrasound; LDRBT = low-dose-rate brachytherapy; RP = radical prostatectomy; SBRT = stereotactic body radiotherapy.

Comment in

References

    1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version I.2019; ed2019. - PubMed
    1. Mahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010–2015. JAMA 2019;321:704–6. - PMC - PubMed
    1. Scherzer ND, DiBiase ZS, Srivastav SK, Thomas R, DiBiase SJ. Regional differences in the treatment of localized prostate cancer: an analysis of surgery and radiation utilization in the United States. Adv Radiat Oncol 2019;4:331–6. - PMC - PubMed
    1. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74. - PubMed
    1. Zumsteg ZS, Spratt DE, Romesser PB, et al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol 2015;194:1624–30. - PMC - PubMed

Publication types

MeSH terms